Ionis Pharmaceuticals (IONS)
(Delayed Data from NSDQ)
$61.17 USD
-0.15 (-0.24%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $61.17 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth A Momentum B VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
IONS 61.17 -0.15(-0.24%)
Will IONS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IONS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IONS
IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome
IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride
IONS: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock
Ionis Beats on Q2 Earnings & Sales, Stock Up 5% on Raised '25 Outlook
Here's What Key Metrics Tell Us About Ionis Pharmaceuticals (IONS) Q2 Earnings
Other News for IONS
Is IONS ready to make a move? NR7 shows up after gaining 0.36%
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Eli Lilly & Co (LLY) and Revvity (RVTY)
Technical picture remains unchanged for IONS after it falls 3.23% on September 15
Insider Sell: Patrick O'Neil Sells 1,700 Shares of Ionis Pharmaceuticals Inc (IONS)
IONS falls 1.33% on September 12, leaving the technical picture intact